The 4151.T stock plunged -18.31% to JPY 2231.00 in pre-market trading on 05 Mar 2026 after Kyowa Kirin (4151.T) said it would stop development of a skin-condition candidate. The move followed Reuters reporting the trial discontinuation and pushed volume to 551000.00 shares, well above recent intraday flow. We examine drivers, metrics and short-term technical levels on the JPX and outline model-based forecasts and risks for investors.

Market move and news drivers

Kyowa Kirin Co., Ltd. (4151.T) fell sharply after the company announced it will discontinue ongoing trials for a dermatology candidate, a Reuters report flagged on 03 Mar 2026. The announcement cut expected pipeline value and triggered a sell-off that set the pre-market price at JPY 2231.00, down JPY 500.00 from the previous close of JPY 2731.00. See Reuters for the initial report source.

Financial snapshot and valuation

Kyowa Kirin trades on JPX with a market cap of JPY 1,167,903,245,080.00 and a trailing PE of 17.43 with EPS 128.02. Key ratios include PB 1.31, EV/EBITDA 8.17, and dividend yield near 2.78%. Revenue and cash metrics remain solid: free cash flow per share 112.53 and cash per share 417.94, but recent operating cash flow growth slowed, reflecting pipeline and R&D timing.

Technical view and trading levels for 4151.T stock

Technically the stock is oversold: RSI 32.09 and CCI -263.17, with Bollinger lower band around JPY 2210.31 acting as near-term support. Short-term resistance sits near the 50-day average JPY 2574.77 and the 200-day at JPY 2490.59. Traders should watch daily volume—today’s 551000.00 versus average 1,313,224.00 for liquidity context and position sizing on JPX.

Meyka AI rates 4151.T with a score out of 100

Meyka AI rates 4151.T with a score of 77.32/100 (Grade B+, Suggestion: BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are model-based and not guaranteed; we are not financial advisors and investors should perform their own due diligence.

Meyka AI forecast and price scenarios

Meyka AI’s forecast model projects a monthly level of JPY 2854.84, a quarterly JPY 2209.06, and a yearly JPY 2004.21. Compared with the current price JPY 2231.00, the monthly projection implies an upside of 28.00%, while the 12-month view implies downside of -10.17%. Forecasts are model-based projections and not guarantees; outcome depends on pipeline updates, sector momentum, and broader market moves.

Risks, catalysts and analyst consensus

Primary near-term risk is pipeline volatility after the trial halt; further R&D setbacks would pressure valuation and earnings. Catalysts that could stabilise the share include new clinical results, licensing deals, or stronger-than-expected sales from existing drugs like Crysvita. Independent coverage is mixed; some metrics (interest coverage 28.07, current ratio 2.72) point to balance-sheet resilience even as growth metrics slow.

Final Thoughts

Kyowa Kirin (4151.T) is a top loser in the pre-market session on 05 Mar 2026, down -18.31% to JPY 2231.00, driven by a Reuters-reported trial discontinuation that trimmed near-term pipeline value. Fundamentals show reasonable valuation metrics—PE 17.43, PB 1.31, free cash flow per share 112.53—and a healthy balance sheet with cash per share 417.94. Meyka AI’s forecast model projects a near-term monthly level of JPY 2854.84, implying an upside of 28.00% from today’s price, while the 12-month projection of JPY 2004.21 implies downside of -10.17%. Investors should weigh the upside scenario against pipeline risk and sector performance in Japan’s healthcare group, and monitor volume and news flow closely. Meyka AI provides this AI-powered market analysis as data-driven context; forecasts and grades are model outputs, not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.